Tandutinib

Research use only, not for human use.

A potent inhibitor of FLT3, Kit and PDGFR with IC50 of 0.22, 0.17 and 0.2 uM, respectively.

A potent inhibitor of FLT3, Kit and PDGFR with IC50 of 0.22, 0.17 and 0.2 uM, respectively; displays 15-20-fold less potent activity against CSF-1R; inhibits IL-3-independent cell growth and FLT3-ITD autophosphorylation with IC50 of 10-100 nM, induces apoptosis and inhibits FLT3-ITD phosphorylation, cellular proliferation and signaling through MAPK and PI3K pathways; exhibits ativity in murine models of FLT3-ITD-mediated disease.Brain Cancer Phase 2 Discontinued

MLN-518;MLN518;CT53518;MLN0518;MLN-0518;CT-53518

Tyrosine Kinase

FLT3

c-Kit;CSF-1R;FLT3;PDGFRβ;Src

Cancer

Brain Cancer

387867-13-2

562.70

C31H42N6O4

>98% (HPLC)

DMSO: ≥ 36 mg/mL

O=C(N1CCN(C2=C3C=C(OC)C(OCCCN4CCCCC4)=CC3=NC=N2)CC1)NC5=CC=C(OC(C)C)C=C5

1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years